Psoriasis Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025

Description

Persistence Market Research has recently released a comprehensive report on the global Psoriasis Drugs Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

Psoriasis Drugs Market Size (2025E): US$ 20.9 Bn
Projected Market Value (2032F): US$ 33.4 Bn
Global Market Growth Rate (CAGR 2025 to 2032): 6.9%

Psoriasis Drugs Market - Report Scope:

The psoriasis drugs market includes a broad spectrum of pharmaceutical treatments aimed at managing and alleviating the symptoms of psoriasis, a chronic autoimmune skin disease. These treatments range from topical agents to advanced biologics and systemic medications. Growing awareness, technological advancements in drug development, and increasing prevalence of psoriasis globally are shaping the demand for more effective therapies. Innovation in biologic drugs and expanding access to dermatological healthcare services continue to drive market momentum.

Market Growth Drivers:

The growth of the global psoriasis drugs market is propelled by the rising prevalence of psoriasis and an increasing number of patients seeking medical treatment due to improved awareness and diagnosis. Technological advancements in biologic therapies, which offer targeted and effective treatment, have significantly expanded treatment options. Favorable reimbursement policies in developed countries and ongoing R&D efforts by pharmaceutical giants have also boosted drug pipeline development. Moreover, the expansion of healthcare infrastructure in emerging economies is facilitating greater access to psoriasis treatments, further driving market growth.

Market Restraints:

Despite the positive outlook, the market faces certain constraints that may hinder its full potential. High costs associated with biologic therapies can limit their accessibility, especially in low- and middle-income regions. Many of these treatments also require long-term use, which can lead to increased healthcare expenses for patients. Additionally, potential side effects, stringent regulatory approvals, and patent expirations for key drugs may impact market dynamics. Limited awareness in rural and underdeveloped areas also restricts the reach of advanced treatments.

Market Opportunities:

The psoriasis drugs market holds promising opportunities due to a growing patient pool and evolving treatment paradigms. The continued development of biosimilars and generic versions of key biologics is expected to make treatments more affordable and widely available. Increasing collaborations between biotech firms and pharmaceutical giants for research and distribution can accelerate innovation and market penetration. Additionally, advancements in personalized medicine and targeted therapies open new avenues for more precise and effective treatment. Expanding digital health platforms and telemedicine services can also enhance diagnosis and treatment accessibility in remote regions.

Key Questions Answered in the Report:

What are the primary factors driving the global psoriasis drugs market's growth?
Which drug classes and modes of administration dominate the market?
How are innovations in biologic therapies influencing market trends?
Who are the key players in the psoriasis drugs market, and what strategies are they adopting?
What are the regional growth patterns and future projections in this sector?

Competitive Intelligence and Business Strategy:

Leading companies in the global psoriasis drugs market, such as Janssen Biotech, Novartis, Amgen, and Pfizer, are prioritizing the development of next-generation biologics and expanding their global footprint through mergers and partnerships. These companies focus on enhancing therapeutic efficacy and minimizing side effects. R&D investment remains a strategic focus, particularly in immunomodulators and interleukin inhibitors. Strategic alliances with biotech startups and clinical trial expansions in developing countries are helping firms broaden their reach and drive competitive differentiation.

Companies Covered in This Report:

Janssen Biotech, Inc.
Novartis International Ltd.
Amgen Inc.
Pfizer Inc.
Takeda Pharmaceutical Company Ltd.
Merck & Co, Inc.
AbbVie Inc.
Eli Lilly and Company
Boehringer Ingelheim GmbH
Sun Pharmaceutical Industries Ltd.
Johnson & Johnson
LEO Pharma
UCB
AstraZeneca
Celgene Corporation

Market Segmentation:

By Drug Class:

Interleukin Inhibitors
Corticosteroids
Anti-inflammatory
Glucocorticoids
TNF alfa Inhibitor
Others

By Mode of Administration:

Topical
Oral
Injectable
Others

By Indication:

Guttate Psoriasis
Inverse Psoriasis
Pustular Psoriasis
Erythrodermic Psoriasis
Plaque Psoriasis
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

By Region:

North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa

Product Code: PMRREP25102

1. Executive Summary

1.1. Global Psoriasis Drugs Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Key Trends
2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Drug Class Adoption Analysis
3.2. Regulatory Landscape
3.3. Pipeline Assessment
3.4. Disease Epidemiology
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Value Chain Analysis
3.8. Porter's Five Force Analysis

4. Global Psoriasis Drugs Market Outlook:

4.1. Key Highlights
- 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
- 4.2.2. Market Size (US$ Mn) Analysis and Forecast, 2025-2032
4.3. Global Psoriasis Drugs Market Outlook: Drug Class
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2019-2024
- 4.3.3. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  - 4.3.3.1. Interleukin Inhibitors
  - 4.3.3.2. Corticosteroids
  - 4.3.3.3. Anti-inflammatory
  - 4.3.3.4. Glucocorticoids
  - 4.3.3.5. Tnf alfa Inhibitor
  - 4.3.3.6. Others
- 4.3.4. Market Attractiveness Analysis: Drug Class
4.4. Global Psoriasis Drugs Market Outlook: Mode of Administration
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Mn) Analysis, By Mode of Administration, 2019-2024
- 4.4.3. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
  - 4.4.3.1. Topical
  - 4.4.3.2. Oral
  - 4.4.3.3. Injectable
  - 4.4.3.4. Others
- 4.4.4. Market Attractiveness Analysis: Mode of Administration
4.5. Global Psoriasis Drugs Market Outlook: Indication
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019-2024
- 4.5.3. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  - 4.5.3.1. Guttate Psoriasis
  - 4.5.3.2. Inverse Psoriasis
  - 4.5.3.3. Pustular Psoriasis
  - 4.5.3.4. Erythrodermic Psoriasis
  - 4.5.3.5. Plaque Psoriasis
  - 4.5.3.6. Others
- 4.5.4. Market Attractiveness Analysis: Indication
4.6. Global Psoriasis Drugs Market Outlook: Distribution Channel
- 4.6.1. Introduction / Key Findings
- 4.6.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2024
- 4.6.3. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  - 4.6.3.1. Hospital Pharmacies
  - 4.6.3.2. Retail Pharmacies
  - 4.6.3.3. e-Commerce
- 4.6.4. Market Attractiveness Analysis: Distribution Channel

5. Global Psoriasis Drugs Market Outlook: Region

5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
5.3. Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region

6. North America Psoriasis Drugs Market Outlook

6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 6.2.1. By Country
- 6.2.2. By Drug Class
- 6.2.3. By Mode of Administration
- 6.2.4. By Indication
- 6.2.5. By Distribution Channel
6.3. Market Size (US$ Mn) Analysis and Forecast By Country, 2025-2032
- 6.3.1. U.S.
- 6.3.2. Canada
6.4. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
- 6.4.1. Interleukin Inhibitors
- 6.4.2. Corticosteroids
- 6.4.3. Anti-inflammatory
- 6.4.4. Glucocorticoids
- 6.4.5. Tnf alfa Inhibitor
- 6.4.6. Others
6.5. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
- 6.5.1. Topical
- 6.5.2. Oral
- 6.5.3. Injectable
- 6.5.4. Others
6.6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 6.6.1. Guttate Psoriasis
- 6.6.2. Inverse Psoriasis
- 6.6.3. Pustular Psoriasis
- 6.6.4. Erythrodermic Psoriasis
- 6.6.5. Plaque Psoriasis
- 6.6.6. Others
6.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 6.7.1. Hospital Pharmacies
- 6.7.2. Retail Pharmacies
- 6.7.3. e-Commerce
6.8. Market Attractiveness Analysis

7. Europe Psoriasis Drugs Market Outlook

7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 7.2.1. By Country
- 7.2.2. By Drug Class
- 7.2.3. By Mode of Administration
- 7.2.4. By Indication
- 7.2.5. By Distribution Channel
7.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Russia
- 7.3.7. Turkey
- 7.3.8. Rest of Europe
7.4. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
- 7.4.1. Interleukin Inhibitors
- 7.4.2. Corticosteroids
- 7.4.3. Anti-inflammatory
- 7.4.4. Glucocorticoids
- 7.4.5. Tnf alfa Inhibitor
- 7.4.6. Others
7.5. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
- 7.5.1. Topical
- 7.5.2. Oral
- 7.5.3. Injectable
- 7.5.4. Others
7.6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 7.6.1. Guttate Psoriasis
- 7.6.2. Inverse Psoriasis
- 7.6.3. Pustular Psoriasis
- 7.6.4. Erythrodermic Psoriasis
- 7.6.5. Plaque Psoriasis
- 7.6.6. Others
7.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 7.7.1. Hospital Pharmacies
- 7.7.2. Retail Pharmacies
- 7.7.3. e-Commerce
7.8. Market Attractiveness Analysis

8. East Asia Psoriasis Drugs Market Outlook

8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Drug Class
- 8.2.3. By Mode of Administration
- 8.2.4. By Indication
- 8.2.5. By Distribution Channel
8.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
8.4. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
- 8.4.1. Interleukin Inhibitors
- 8.4.2. Corticosteroids
- 8.4.3. Anti-inflammatory
- 8.4.4. Glucocorticoids
- 8.4.5. Tnf alfa Inhibitor
- 8.4.6. Others
8.5. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
- 8.5.1. Topical
- 8.5.2. Oral
- 8.5.3. Injectable
- 8.5.4. Others
8.6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 8.6.1. Guttate Psoriasis
- 8.6.2. Inverse Psoriasis
- 8.6.3. Pustular Psoriasis
- 8.6.4. Erythrodermic Psoriasis
- 8.6.5. Plaque Psoriasis
- 8.6.6. Others
8.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 8.7.1. Hospital Pharmacies
- 8.7.2. Retail Pharmacies
- 8.7.3. e-Commerce
8.8. Market Attractiveness Analysis

9. South Asia & Oceania Psoriasis Drugs Market Outlook

9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Drug Class
- 9.2.3. By Mode of Administration
- 9.2.4. By Indication
- 9.2.5. By Distribution Channel
9.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
9.4. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
- 9.4.1. Interleukin Inhibitors
- 9.4.2. Corticosteroids
- 9.4.3. Anti-inflammatory
- 9.4.4. Glucocorticoids
- 9.4.5. Tnf alfa Inhibitor
- 9.4.6. Others
9.5. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
- 9.5.1. Topical
- 9.5.2. Oral
- 9.5.3. Injectable
- 9.5.4. Others
9.6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 9.6.1. Guttate Psoriasis
- 9.6.2. Inverse Psoriasis
- 9.6.3. Pustular Psoriasis
- 9.6.4. Erythrodermic Psoriasis
- 9.6.5. Plaque Psoriasis
- 9.6.6. Others
9.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 9.7.1. Hospital Pharmacies
- 9.7.2. Retail Pharmacies
- 9.7.3. e-Commerce
9.8. Market Attractiveness Analysis

10. Latin America Psoriasis Drugs Market Outlook

10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Drug Class
- 10.2.3. By Mode of Administration
- 10.2.4. By Indication
- 10.2.5. By Distribution Channel
10.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
10.4. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
- 10.4.1. Interleukin Inhibitors
- 10.4.2. Corticosteroids
- 10.4.3. Anti-inflammatory
- 10.4.4. Glucocorticoids
- 10.4.5. Tnf alfa Inhibitor
- 10.4.6. Others
10.5. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
- 10.5.1. Topical
- 10.5.2. Oral
- 10.5.3. Injectable
- 10.5.4. Others
10.6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 10.6.1. Guttate Psoriasis
- 10.6.2. Inverse Psoriasis
- 10.6.3. Pustular Psoriasis
- 10.6.4. Erythrodermic Psoriasis
- 10.6.5. Plaque Psoriasis
- 10.6.6. Others
10.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 10.7.1. Hospital Pharmacies
- 10.7.2. Retail Pharmacies
- 10.7.3. e-Commerce
10.8. Market Attractiveness Analysis

11. Middle East & Africa Psoriasis Drugs Market Outlook

11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Drug Class
- 11.2.3. By Mode of Administration
- 11.2.4. By Indication
- 11.2.5. By Distribution Channel
11.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 11.3.1. GCC Countries
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
11.4. Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
- 11.4.1. Interleukin Inhibitors
- 11.4.2. Corticosteroids
- 11.4.3. Anti-inflammatory
- 11.4.4. Glucocorticoids
- 11.4.5. Tnf alfa Inhibitor
- 11.4.6. Others
11.5. Market Size (US$ Mn) Analysis and Forecast, By Mode of Administration, 2025-2032
- 11.5.1. Topical
- 11.5.2. Oral
- 11.5.3. Injectable
- 11.5.4. Others
11.6. Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
- 11.6.1. Guttate Psoriasis
- 11.6.2. Inverse Psoriasis
- 11.6.3. Pustular Psoriasis
- 11.6.4. Erythrodermic Psoriasis
- 11.6.5. Plaque Psoriasis
- 11.6.6. Others
11.7. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 11.7.1. Hospital Pharmacies
- 11.7.2. Retail Pharmacies
- 11.7.3. e-Commerce
11.8. Market Attractiveness Analysis

12. Competition Landscape

12.1. Market Share Analysis, 2025
12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Janssen Biotech, Inc.
  - 12.3.1.1. Overview
  - 12.3.1.2. Segments and Drug Class
  - 12.3.1.3. Key Financials
  - 12.3.1.4. Market Developments
  - 12.3.1.5. Market Strategy
- 12.3.2. Novartis International Ltd.
- 12.3.3. Amgen Inc.
- 12.3.4. Pfizer Inc.
- 12.3.5. Takeda Pharmaceutical Company Ltd.
- 12.3.6. Merck & Co, Inc.
- 12.3.7. AbbVie Inc.
- 12.3.8. Eli Lilly and Company
- 12.3.9. Boehringer Ingelheim GmbH
- 12.3.10. Sun Pharmaceutical Industries Ltd.
- 12.3.11. Johnson & Johnson
- 12.3.12. LEO Pharma
- 12.3.13. UCB
- 12.3.14. AstraZeneca
- 12.3.15. Celgene Corporation
- 12.3.16. Arcutis Biotherapeutics, Inc.
- 12.3.17. Others

13. Appendix

13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations

Psoriasis Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032